133 result(s)
GSK Medical
This online medical resource for scientific and clinical information is intended to share the latest development in clinical research on GSK Products
Clinical Efficacy
As well as ease of use, and having a low number of errors with an inhaler, patients need treatments that show clinical efficacy.
Patient Benefits
What are the key considerations affecting inhaler choice, from a patient and physician perspective?
The EMAX Trial
Explore the evidence for initial maintenance treatment with dual bronchodilators compared with bronchodilator monotherapy
NMA class comparison data in COPD
UMEC/VI versus dual and mono-bronchodilator therapies
Network meta-analysis (NMA)
Comparing efficacy of dual therapies among patients with COPD
Summary
For UMEC/VI the NMA showed outcome benefits compared with other single-inhaler LAMA/LABA dual therapies and monotherapies¹
NMA class comparison data in COPD
FF/UMEC/VI versus triple and dual bronchodilator therapies
Summary
For FF/UMEC/VI, the NMA suggest favourable efficacy compared with other single-inhaler triple therapies.1
Network meta-analysis (NMA)
Comparing efficacy of triple therapies among patients with COPD
GSK Medical - Please request a contact confirmation Form
Contact us form for UK healthcare professionals to contact GSK
Inhaled molecules for COPD treatment
How does molecule pharmacology correlate with clinical efficacy and safety?
Technical Performance
Explore the technical performance of inhalers
Effectiveness and safety in patients with autoimmune diseases
Real-world evidence supporting protection from HZ in individuals with selected autoimmune diseases
Respiratory
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas rhoncus augue nunc, quis consectetur tortor malesuada at curabitur. Dolor sit amet, consectetur adipiscing elit. Maecenas rhoncus aug nunc, quis consectetur tortor malesuada at curabitur.
O que sabe sobre o vsr e vacina RSVPreF3?
Espaço online onde pode aprofundar os seus conhecimentos sobre o Vírus Sincicial Respiratório e vacina RSVPreF3
EOS Talks Digital Classroom – SEA
EOS Talks Digital Classroom é o seu espaço online onde pode aprofundar os seus conhecimentos sobre a incidência, controlo e tratamento das doenças eosinofílicas
EOS Talks Digital Classroom – EGPA
EOS Talks Digital Classroom é o seu espaço online onde pode aprofundar os seus conhecimentos sobre a incidência, controlo e tratamento das doenças eosinofílicas
Unmet Need
In this section the symptom burden and unmet needs of patients with COPD are discussed, as well as the importance of correct inhaler technique and the impact of multiple inhaler therapy.
Disease Information
View disease information content from GSK Vaccines
Resources
View resources from medical organizations, patient advocacy organizations as well as global and local guidelines.
Vaccines
GSK Vaccines Medical
Herpes Zoster
Herpes zoster, also known as shingles, is a painful condition caused by reactivation of the varicella zoster virus, the same virus that causes chickenpox.1-4
Infection, latency and reactivation
Educational content on herpes zoster (shingles) for healthcare professionals
Varicella (chickenpox) versus herpes zoster (shingles)
Educational content on herpes zoster (shingles) for healthcare professionals
Misunderstandings among adults
Educational content on herpes zoster (shingles) for healthcare professionals
Incidence
Educational content on herpes zoster (shingles) for healthcare professionals
Burden of disease and complications
Burden of disease and complications
Epidemiology and risk factors
Herpes zoster is caused by the reactivation of the varicella zoster virus.
What is herpes zoster (shingles)?
Educational content on herpes zoster (shingles) for healthcare professionals
Identifying patients at risk
Educational content on herpes zoster (shingles) for healthcare professionals
Signs and symptoms
Educational content on herpes zoster (shingles) for healthcare professionals
ZOE programme
The efficacy of the Recombinant Zoster Vaccine (RZV) was evaluated in two Phase 3 clinical trials, Zoster Efficacy Study in Adults 50 Years of Age or Older (ZOE-50, NCT01165177) and Zoster Efficacy Study in Adults 70 Years of Age or Older (ZOE-70, NCT01165229).1,2 The ZOE-LTFU (NCT02723773) is a long-term follow-up (LTFU) study of the ZOE-50 and ZOE-70 pivotal trials.3,4
Importance of cell-mediated immunity
Educational content on herpes zoster (shingles) for healthcare professionals
Complications
Educational content on herpes zoster (shingles) for healthcare professionals
Co-administration of the recombinant zoster vaccine (RZV) with other adult vaccines
Throughout life, vaccines are recommended to protect individuals from vaccine-preventable diseases.
Prevention through vaccination: Immunocompromised patients
Efficacy, immunogenicity, and safety of the adjuvanted recombinant zoster vaccine (RZV) in immunocompromised subjects
Real-world evidence for the recombinant zoster vaccine (RZV)
Since the first approval of the recombinant zoster vaccine (RZV) against herpes zoster (HZ) in 2017, evidence for its use in real-world settings has been generated through real-world studies.
Real world evidence for RZV in patients with autoimmune diseases
Real world evidence for RZV in patients with autoimmune diseases
Multidisciplinary approach to patient care
Educational content on herpes zoster (shingles) for healthcare professionals
Conservative measures
Educational content on herpes zoster (shingles) for healthcare professionals
Scenario 2: An unusual presentation
Educational content on herpes zoster (shingles) for healthcare professionals
Patient management
Treatment options for herpes zoster are suboptimal and may have limited efficacy and poor tolerability in some patients. Therefore, improvements are needed in the prevention and management of herpes zoster.1,2
Scenario 1: A high-risk patient
Educational content on herpes zoster (shingles) for healthcare professionals
IL-5 Meetings 2025
Espaço online onde pode aprofundar os seus conhecimentos sobre o papel pleotrópico da Interleucina 5 (IL-5).
IL-5 Meetings
Espaço online onde pode aprofundar os seus conhecimentos sobre o papel pleotrópico da Interleucina 5 (IL-5).
The history of vaccines
Educational content on vaccines for healthcare professionals
Discussing vaccines with patients
Educational content on vaccines for healthcare professionals
What is an adjuvanted vaccine?
Educational content on vaccines for healthcare professionals
The expanding role of vaccines
Educational content on vaccines for healthcare professionals
What influences decisions about vaccination?
Educational content on vaccines for healthcare professionals
MF360 2025
Espaço online onde pode assitir aos webinares MF360 sobre os desafios na mielofibrose.
Vaccinology
Educational content on vaccines for healthcare professionals
Different types of vaccines
Educational content on vaccines for healthcare professionals
Immunogenicity and Safety in 50–59 YOA
Immunogenicity and Safety in 50–59 YOA
Risk Factors and Clinical Burden of RSV in Older Adults
While RSV-related infections usually present as mild cold-like symptoms in adults, some cases may lead to more serious respiratory complications, hospitalization and death, particularly in older adults and those with underlying conditions1
Respiratory Syncytial Virus
RSV is a common cause of acute respiratory illness in infants, older adults, and adults with underlying medical conditions.
Load more
Não conseguimos encontrar a informação que procura. Experimente os seguintes passos para melhorar a sua pesquisa:
- Verifique a ortografia do termo de pesquisa
- Experimente um termo de pesquisa diferente
- Tente utilizar várias palavras-chave para restringir a sua pesquisa
- Tente utilizar sinónimos ou palavras relacionadas para alargar a sua pesquisa